Replimune Shares Face Pivotal FDA Decision on RP1 Therapy

FDA decision on Replimune's RP1 for melanoma will determine company's future, impacting stock volatility and its financial runway into 2027.

The coming days represent a critical juncture for Replimune Group Inc., as the U.S. Food and Drug Administration (FDA) is set to deliver its verdict on the company's lead immunotherapy candidate, RP1. The regulatory review period concludes on Friday, April 10, marking a decisive moment for the firm's commercial strategy following a previous setback.

Financial and Market Stakes Heighten Tension

Market participants are bracing for significant volatility. Shares experienced an approximate 11% surge last Thursday, while options trading indicates exceptionally high expected price swings in the near term. The outcome will likely trigger substantial movement in either direction.

Financially, the company reported cash and equivalents of about $269 million. With a current quarterly cash burn rate near $75 million, this provides a theoretical operating runway into the first quarter of 2027. To bolster its financial flexibility for a potential commercial launch, Replimune has already amended and extended credit agreements with Hercules Capital. A negative decision from regulators would sharply increase pressure on these reserves and critically shorten the timeline to the next major clinical opportunity.

A Second Attempt at Regulatory Approval

At the heart of the matter is the Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. The path to this point has been challenging. The FDA rejected the initial application in July 2025, citing concerns over the heterogeneity of patient populations within the supporting clinical trial data. In response, Replimune resubmitted the application in October, providing additional analyses aimed at addressing the agency's feedback.

Clinical Data Underpinning the Submission

The resubmission is supported by findings from the IGNYTE clinical trial. In this study, the combination therapy demonstrated an objective response rate of 32.9% in patients who had previously ceased responding to standard treatments. Securing FDA approval would grant Replimune access to a market segment with limited therapeutic alternatives for this specific patient group.

Thus, the April 10 decision carries weight far beyond a single regulatory milestone. It stands as a pivotal event that will shape the company's medical impact and determine its long-term financial stability.